One safety concern. Multiple regulatory responses. One important question for global pharmacovigilance: what should happen next in every market where these products are authorised?
The third quarter of 2026 has brought an important pharmacovigilance development around ferric carboxymaltose (FCM) and the risk of hypophosphataemia.
On 1 September 2026, the US FDA required a boxed warning for ferric carboxymaltose injection concerning symptomatic hypophosphataemia. The FDA’s assessment used multiple evidence sources, including its adverse-event database, published literature and the Sentinel System. FDA also found that serum phosphate testing occurred in fewer than 20% of ferric carboxymaltose administration episodes in the Sentinel data reviewed.
Only days later, EMA’s Pharmacovigilance Risk Assessment Committee initiated a review of injectable iron-containing medicines. The review is examining hypophosphataemia and related bone complications, including osteomalacia, as well as the effectiveness of existing risk-minimisation measures.
This makes the story bigger than a label change.
It raises a fundamental pharmacovigilance question:
If a safety risk is already known, but the risk-minimisation measure may not be producing the intended behaviour in clinical practice, what should regulators and MAHs do next?
What happened?
FDA: From warning to boxed warning
The FDA has strengthened the US prescribing information for ferric carboxymaltose to highlight the risk of symptomatic hypophosphataemia.
This is not a newly identified adverse reaction.
FDA had previously strengthened the Injectafer label:
- 2020: warning added concerning serious symptomatic hypophosphataemia
- 2023: phosphate-monitoring recommendations added for patients at risk and those receiving repeat treatment within three months
- 2025: additional risk factors were added
- 2026: FDA escalated the warning to a boxed warning following a further assessment using FAERS/AEMS, literature and Sentinel data.
The regulatory question has therefore evolved from:
“Is there a risk?”
to:
“Are existing measures sufficiently effective to control the risk?”
EMA: Looking beyond one product
EMA’s PRAC has initiated an EU-wide review of parenteral iron-containing medicines.
The review includes ferric carboxymaltose, ferric derisomaltose, iron dextran, ferric gluconate, ferric hydroxide polymaltose complex and iron sucrose.
Importantly, EMA is not assuming that all injectable iron products have identical risk profiles.
Rather, it is assessing whether the available evidence warrants regulatory changes across the relevant products.
The review was triggered by serious cases, including cases of osteomalacia, and reports of hypophosphataemia after only one or two FCM doses, including in patients without recognised risk factors. EMA also identified potential delays in diagnosis because symptoms such as fatigue, muscle pain and bone pain can overlap with iron-deficiency symptoms.
EMA’s referral documentation reports 793 suspected post-marketing cases involving hypophosphataemia-related terms between January 2023 and June 2026; 81% were classified as serious. The analysis identified that 767 involved hypophosphatemia with only one suspected medicinal product. The data indicate that clinically significant hypophosphatemia can occur even after one or two doses or limited exposure, contradicting the current focus on long term and high dose treatment.
International Regulatory Response
UK MHRA: Risk already recognised and reinforced
The UK has been communicating the risk of symptomatic hypophosphataemia with ferric carboxymaltose for several years.
The MHRA advises monitoring serum phosphate in patients:
- receiving multiple higher-dose administrations
- receiving long-term treatment
- with pre-existing risk factors such as vitamin-D deficiency, malabsorption, secondary hyperparathyroidism, inflammatory bowel disease or osteoporosis.
Healthcare professionals are also advised to reconsider treatment where hypophosphataemia persists.
Importantly, a September 2026 post-publication note clarifies that the risks described in the MHRA communication apply to all ferric carboxymaltose products, not only the originally referenced Ferinject brand.
The UK example illustrates that regulatory action does not necessarily begin with a new warning.
It can involve clarifying the scope and applicability of an existing safety measure across products containing the same active substance.
Australia TGA: Earlier action and continued monitoring
Australia’s TGA has previously recognised symptomatic hypophosphataemia as a known risk with ferric carboxymaltose.
TGA advised healthcare professionals to evaluate patient risk factors before treatment and follow up patients considered at risk. Its safety review also highlighted the possibility that persistent fatigue, weakness or other symptoms could be incorrectly attributed to continuing iron-deficiency anaemia rather than hypophosphataemia.
TGA’s earlier pharmacovigilance review identified reports of hypophosphataemia with ferric carboxymaltose, including severe cases and skeletal manifestations.
The Australian experience demonstrates the value of longitudinal safety surveillance: a known risk can remain clinically important even when it has already been reflected in product information.
Hong Kong: An example of active regulatory intelligence
Hong Kong provides perhaps the most interesting example for this discussion.
Following earlier international safety communications, Hong Kong’s Pharmacy and Poisons Board decided in December 2020 that the sales-pack label and/or package insert for registered ferric carboxymaltose products should include safety information concerning:
- hypophosphataemia
- hypophosphataemic osteomalacia
- serum phosphate monitoring in patients with risk factors
- monitoring in patients receiving multiple higher-dose administrations or long-term treatment.
Following the FDA’s September 2026 boxed warning, Hong Kong’s Department of Health issued another safety communication.
It reported that Hong Kong had two registered ferric carboxymaltose products and that, at that time, it had received one ADR report involving ferric carboxymaltose, although that case was not related to hypophosphataemia.
More importantly, Hong Kong stated that it would remain vigilant regarding the outcome of the EMA review and safety updates from other regulatory authorities and consider whether further local action was necessary.
This is the regulatory-intelligence model in action:
International regulatory signal → local assessment → monitor emerging evidence → determine whether local action is warranted.
What does this mean for India?
The recent FDA and EMA developments are also relevant from an Indian regulatory-intelligence perspective.
India has an established pharmacovigilance framework through CDSCO and the Pharmacovigilance Programme of India (PvPI), and Indian regulatory authorities periodically issue safety alerts, label-related directions and other communications in response to emerging safety information.
As of 29 September 2026, we have not identified a publicly available CDSCO or PvPI communication specifically addressing the latest FDA boxed warning for ferric carboxymaltose or the ongoing EMA review of parenteral iron-containing medicines.
This is worth monitoring as the international regulatory assessments evolve.
The absence of a specific public communication at this stage does not necessarily indicate that no assessment is taking place. Regulatory authorities may review emerging evidence through their established pharmacovigilance and regulatory processes before determining whether any local action is warranted.
What should Indian MAHs be watching?
For companies manufacturing or marketing ferric carboxymaltose in India, the international developments provide an important regulatory-intelligence input.
Areas worth reviewing include:
- the emerging FDA and EMA assessments of hypophosphataemia;
- the company’s cumulative global and Indian safety data;
- cases involving severe or symptomatic hypophosphataemia and hypophosphataemic osteomalacia;
- relevant risk factors and repeat/high-dose exposure;
- current Indian product information and risk-minimisation measures;
- the company’s assessment of regulatory actions in other markets; and
- any implications for ongoing aggregate safety assessment, signal management or benefit-risk evaluation.
The key consideration for a global MAH is not necessarily whether the same regulatory action should be replicated in India, but whether new international evidence changes the company’s assessment of its product in the Indian market.
As the EMA review progresses and other regulators continue to assess the emerging evidence, the regulatory landscape for parenteral iron products may become clearer.
For Indian PV professionals, this is therefore a developing regulatory-intelligence story rather than a concluded regulatory position.
Global Regulatory Perspective: What Does This Mean Across Markets
A regulatory action in one market does not automatically become a regulatory action everywhere.
For a global MAH, however, it is an important regulatory-intelligence signal that warrants assessment across markets.
The ferric carboxymaltose story illustrates this well:
- FDA has escalated the US warning following continued evidence of clinically significant hypophosphataemia.
- EMA is undertaking a broader review of parenteral iron medicines and existing risk-minimisation measures.
- MHRA has existing safety measures and has clarified that the identified risks apply to all ferric carboxymaltose products.
- TGA has previously issued safety advice concerning hypophosphataemia with ferric carboxymaltose.
- Hong Kong is monitoring the international regulatory developments and the outcome of the EMA review.
- PMDA revised precautions for ferric carboxymaltose and saccharated ferric oxide in June 2026.
For India, this is particularly relevant given the country’s position as a major global manufacturer and marketer of medicines, including generic products.
For companies operating across multiple markets, timely awareness of international safety signals and regulatory actions is therefore important for assessing whether emerging evidence has implications for their Indian products, safety data, product information and risk-minimisation measures.
The regulatory response will, of course, depend on the evidence and requirements applicable in each jurisdiction.
The broader regulatory-intelligence lesson is simple:
When one major regulator acts on a safety concern, global MAHs need to understand not only what changed in that market, but whether the underlying evidence has implications for their products and patients elsewhere.
